Literature DB >> 18640460

Polymyalgia rheumatica and giant-cell arteritis.

Carlo Salvarani1, Fabrizio Cantini, Gene G Hunder.   

Abstract

Polymyalgia rheumatica and giant-cell arteritis are closely related disorders that affect people of middle age and older. They frequently occur together. Both are syndromes of unknown cause, but genetic and environmental factors might have a role in their pathogenesis. The symptoms of polymyalgia rheumatica seem to be related to synovitis of proximal joints and extra-articular synovial structures. Giant-cell arteritis primarily affects the aorta and its extracranial branches. The clinical findings in giant-cell arteritis are broad, but commonly include visual loss, headache, scalp tenderness, jaw claudication, cerebrovascular accidents, aortic arch syndrome, thoracic aorta aneurysm, and dissection. Glucocorticosteroids are the cornerstone of treatment of both polymyalgia rheumatica and giant-cell arteritis. Some patients have a chronic course and might need glucocorticosteroids for several years. Adverse events of glucocorticosteroids affect more than 50% of patients. Trials of steroid-sparing drugs have yielded conflicting results. A greater understanding of the molecular mechanisms involved in the pathogenesis should provide new targets for therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18640460     DOI: 10.1016/S0140-6736(08)61077-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  156 in total

1.  [Therapy of vasculitides: according to recommendations of the European League Against Rheumatism (EULAR) and European Vasculitis Study Group (EUVAS)].

Authors:  J U Holle; F Moosig; W L Gross
Journal:  Internist (Berl)       Date:  2011-06       Impact factor: 0.743

2.  The impact of 18F-FDG PET on the management of patients with suspected large vessel vasculitis.

Authors:  Martin Fuchs; Matthias Briel; Thomas Daikeler; Ulrich A Walker; Helmut Rasch; Scott Berg; Quinn K T Ng; Heike Raatz; David Jayne; Ina Kötter; Daniel Blockmans; Maria C Cid; Sergio Prieto-González; Peter Lamprecht; Carlo Salvarani; Zaharenia Karageorgaki; Richard Watts; Raashid Luqmani; Jan Müller-Brand; Alan Tyndall; Martin A Walter
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-11-10       Impact factor: 9.236

Review 3.  Anti-TNF therapy for polymyalgia rheumatica: report of 99 cases and review of the literature.

Authors:  Nádia Emi Aikawa; Rosa Maria Rodrigues Pereira; Laís Lage; Eloisa Bonfá; Jozélio Freire Carvalho
Journal:  Clin Rheumatol       Date:  2012-01-11       Impact factor: 2.980

4.  Clinical course and management of a consecutive series of patients with "healed temporal arteritis".

Authors:  Yvonne C Lee; Robert F Padera; Erika H Noss; Anne H Fossel; Don Bienfang; Matthew H Liang; William P Docken
Journal:  J Rheumatol       Date:  2011-12-01       Impact factor: 4.666

5.  Parameters related to a positive test result for FDG PET(/CT) for large vessel vasculitis: a multicenter retrospective study.

Authors:  G A Hooisma; H Balink; P M Houtman; R H J A Slart; K D F Lensen
Journal:  Clin Rheumatol       Date:  2012-02-10       Impact factor: 2.980

Review 6.  Recent advances in diagnostic strategies for giant cell arteritis.

Authors:  Tanaz A Kermani; Kenneth J Warrington
Journal:  Curr Neurol Neurosci Rep       Date:  2012-04       Impact factor: 5.081

7.  Panaortitis heralding giant cell temporal arteritis.

Authors:  Brigitte Granel; Pascal Rossi; Sandrine Marciano; Fanny Bernard; Karim Aissi; Yves Frances
Journal:  BMJ Case Rep       Date:  2010-03-17

Review 8.  Rational use of blood tests in the evaluation of rheumatic diseases.

Authors:  Chokkalingam Siva; Emily C Larson; Mark Barnett
Journal:  Mo Med       Date:  2012 Jan-Feb

9.  Diagnosis and management of giant cell arteritis.

Authors:  Kevin Barraclough; Christian D Mallen; Toby Helliwell; Samantha L Hider; Bhaskar Dasgupta
Journal:  Br J Gen Pract       Date:  2012-06       Impact factor: 5.386

Review 10.  Giant cell arteritis: epidemiology, diagnosis, and management.

Authors:  Miguel A Gonzalez-Gay; Cristina Martinez-Dubois; Mario Agudo; Orlando Pompei; Ricardo Blanco; Javier Llorca
Journal:  Curr Rheumatol Rep       Date:  2010-12       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.